Which prostate cancer drug is kinder to your brain? new study aims to find out
NCT ID NCT04335682
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug causes fewer mental side effects than the other.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darolutamide and enzalutamide
What this could lead to
If successful, this study could help doctors choose which drug is less likely to cause thinking or memory problems in men with prostate cancer.
What could go wrong
This is a small, early-phase study (111 participants) that only measures cognitive changes, not overall survival or cancer control. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
University of California - San Francisco at Mount Zion
San Francisco, California, 94115, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States